← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2014Last known activity
Jan 31, 2026
Timeline
2000s
- Jan 1, 2009
The Marcus Foundation— Founded
Drugs by trial phase (19 distinct, 16 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (7 own, 0 via acquisition)
Phase 2 (4 own, 0 via acquisition)
Indications
Studied for
- Adrenoleukodystrophy
- alpha-Mannosidosis
- Autism Spectrum Disorder
- Autistic Disorder
- Brain Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Brain Injuries
- Cerebral Palsy
- Child Development Disorders, Pervasive
- Coronavirus Infections
- Disease
- Leukodystrophy, Globoid Cell
- Leukodystrophy, Metachromatic
- Mannosidase Deficiency Diseases
- Metabolic Diseases
- Mucopolysaccharidoses
- Mucopolysaccharidosis II
- Neuronal Ceroid-Lipofuscinoses
- Niemann-Pick Diseases
- Niemann-Pick Disease, Type A
- Niemann-Pick Disease, Type C
- Osteoarthritis
- Pelizaeus-Merzbacher Disease
- Pick Disease of the Brain
- Sandhoff Disease
- Sepsis
- Severe Acute Respiratory Syndrome
- Stroke
- Tay-Sachs Disease
- Toxemia
Recent trials (16)
- NCT06996652CollaboratorPhase 2Jan 31, 2026
- NCT06464588CollaboratorPhase 1Oct 31, 2024
- NCT05743946CollaboratorPhase 4Apr 18, 2023
- NCT05501548CollaboratorPhase 2Dec 31, 2022
- NCT05035862CollaboratorPhase 1Jan 31, 2022
- NCT04484077CollaboratorPhase 1Nov 30, 2021
- NCT04399889CollaboratorPhase 1/Phase 2Jun 1, 2020
- NCT04294290CollaboratorPhase 1Apr 1, 2020
- NCT04089579CollaboratorPhase 2Oct 1, 2019
- NCT03818737CollaboratorPhase 3Mar 28, 2019
- NCT03509350CollaboratorPhase 3Aug 22, 2018
- NCT03473301CollaboratorPhase 1/Phase 2Apr 4, 2018
- NCT03099239CollaboratorPhase 1Jun 6, 2017
- NCT03004976CollaboratorPhase 2Mar 14, 2017
- NCT02254863CollaboratorPhase 1Sep 1, 2014
Details
- Founded
- Denver, CO, US Jan 1, 2009
- Last known activity
- Jan 31, 2026